PanGenex Engages Phillips Sales & Marketing
June 13 2011 - 7:00AM
Business Wire
PanGenex Corporation (“PanGenex” or “the Company”) (Pink Sheets:
PGCX), a nutraceutical and dietary supplement developer, announced
today that it has engaged Philips Sales & Marketing, Inc. (PSM)
as its agent to sell its products through mail order catalogs,
small chain stores including independent health food stores and
pharmacies as well as three of the nation’s largest drug store
chains. PSM will also provide marketing and advertising services
for the Company.
The Company has allotted a marketing and advertising budget to
build brand awareness and drive sales of its nutraceutical
products. “We are excited to work with PSM because of their
extensive experience in marketing and distributing nutraceutical
products to the nation’s largest pharmacy retailers,” stated John
Stanton, Chairman of PanGenex.
Brett Phillips, President of Phillips Sales & Marketing
stated, "We are very impressed with PanGenex’s line of quality
products and the professional staff they have assembled to supply
our pipe line with cutting edge health products that should offer
nutritional and health benefits to potentially millions of people
not just in the U.S. but abroad as well.
About Phillips Sales & Marketing, Inc.
Phillips Sales & Marketing, Inc. advertises, markets and
distributes proprietary and non-proprietary nutraceutical and
dietary supplements and other nondurable consumer products. PSM is
a vendor for the largest retail pharmacy chains in the United
States as well as smaller independent drug and health food stores
and maintains relationships with independent brokers representing
product specific mail order catalogs. PSM’s unique ad campaign is
designed to educate and engage the target audience to procure sales
while providing the client with highly advantageous rates.
About PanGenex Corporation
PanGenex Corporation pursues business opportunities in the $70
billion nutraceutical and dietary supplement industry. With a focus
on the cardiovascular health segment, PanGenex develops and markets
sector-leading, patented or patent-pending, condition-specific
nutraceuticals and topical over-the-counter (OTC) drugs and
personal care products. PanGenex principal products Calci-Clear,
LIPIDEME and Omeganol, address Soft Tissue Calcification (STC), an
abnormal hardening or thickening of soft tissues (such as arteries)
which is linked to over 50% of chronic diseases and presently
affects an estimated 196 million or 60 percent of all Americans.
Many of its products contain the purest grade of nutraceutical
components available anywhere without a prescription. Since 2006,
PanGenex has voluntarily submitted its product labels to the FDA
without incidence. PanGenex products are sold to healthcare
practitioners in 20 U.S. states, Canada, Puerto Rico, Canada,
Brazil and Australia, in fine retail establishments and on the
Internet at www.HeartHealthyWorld.com.
This press release contains "forward-looking statements," which
are statements related to future, not past, events. In this
context, the forward-looking statements often include statements
regarding our goals, plans, projections and guidance regarding our
financial position, results of operations, market position, pending
and potential future acquisitions and business strategy, and often
contain words such as "expects," "anticipates," "intends," "plans,"
"believes," "seeks" or "will." Any such forward-looking statements
are not assurances of future performance and involve risks and
uncertainties that may cause results to differ materially from
those set forth in the statements. These risks and uncertainties
include, among other things, (a) general economic and business
conditions, (b) the level of strategic partner incentives, (c) the
future regulatory environment, (d) our cost of financing, (e) our
ability to complete acquisitions and dispositions and the risks
associated therewith, and (f) our ability to retain key personnel.
These factors, as well as additional factors, could affect our
forward-looking statements. We urge you to carefully consider this
information. We undertake no duty to update our forward-looking
statements, including our earnings outlook. The statements in this
press release have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat,
cure or prevent any disease.